Rupert W. Jakes
YOU?
Author Swipe
View article: Prospective REALITI-A Study
Prospective REALITI-A Study Open
View article: Burden of eosinophilic granulomatosis with polyangiitis in Europe
Burden of eosinophilic granulomatosis with polyangiitis in Europe Open
Background and aims Real-world evidence characterising the burden of eosinophilic granulomatosis with polyangiitis (EGPA) in Europe is limited. The aim of this study was to characterise patients in a large European EGPA cohort. Methods Thi…
View article: Disparate kinetics in immune response of two different <i>Haemophilus influenzae</i> type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule
Disparate kinetics in immune response of two different <i>Haemophilus influenzae</i> type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule Open
Since the introduction of Haemophilus Influenzae type b (Hib) conjugate vaccines, invasive Hib disease has strongly declined worldwide, yet continued control of Hib disease remains important. In Europe, currently three different hex…
View article: Prevalence, incidence and healthcare burden of eosinophilic granulomatosis with polyangiitis in the UK
Prevalence, incidence and healthcare burden of eosinophilic granulomatosis with polyangiitis in the UK Open
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease characterised by the combination of small-to-medium vessel vasculitis, blood and tissue eosinophilia, and asthma and/or sinonasal disease. This s…
View article: Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis Open
View article: An algorithm‐based approach to ascertain patients with rare diseases in electronic health records using hypereosinophilic syndrome as an example
An algorithm‐based approach to ascertain patients with rare diseases in electronic health records using hypereosinophilic syndrome as an example Open
Purpose Improved hypereosinophilic syndrome (HES) ascertainment in electronic health record (EHR) databases may improve disease understanding and management. An algorithm to ascertain and characterize this rare condition was therefore deve…
View article: Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization
Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization Open
Patients with HES across 5 European countries had a substantial disease burden despite extensive oral corticosteroids treatment, highlighting the need for additional targeted therapies.
View article: Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis
Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis Open
Background An objective of the Severe Heterogeneous Asthma Registry, Patient-centered (SHARP) is to produce real-world evidence on a pan-European scale by linking nonstandardised, patient-level registry data. Mepolizumab has shown clinical…
View article: Real World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A
Real World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A Open
View article: Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility
Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility Open
View article: Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A
Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A Open
View article: Knowledge and Attitude Among Patients and Physicians on Allergic Rhinitis (KAPPA): An International Survey
Knowledge and Attitude Among Patients and Physicians on Allergic Rhinitis (KAPPA): An International Survey Open
Patient and physician perceptions of AR mostly differed between and within countries, although there was generally agreement that AR could be controlled with treatment. Differing attitudes towards AR among patients and physicians suggests …
View article: REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma
REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma Open
This 1-year analysis demonstrates that real-world mepolizumab treatment is clinically effective in patients with severe asthma, providing disease control while reducing the need for mOCS and SCS bursts.
View article: Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis
Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis Open
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disease associated with vascular inflammation and multisystem organ damage. The literature reporting EGPA incidence or prevalence is limited. We performed a systematic literatu…
View article: International Differences in the Use of Mepolizumab to Treat Severe Asthma - Impact of Reimbursement Policies
International Differences in the Use of Mepolizumab to Treat Severe Asthma - Impact of Reimbursement Policies Open
View article: A 6-year safety surveillance of 10-valent pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D conjugate vaccine (PHiD-CV) in South Korea
A 6-year safety surveillance of 10-valent pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D conjugate vaccine (PHiD-CV) in South Korea Open
In 2010, Korea introduced 10-valent pneumococcal conjugate vaccine for children aged 6 weeks to 5 years against invasive disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactive …
View article: Community-Acquired Pneumonia Case Validation in an Anonymized Electronic Medical Record–Linked Expert System
Community-Acquired Pneumonia Case Validation in an Anonymized Electronic Medical Record–Linked Expert System Open
An electronic anonymized patient portal analysis using radiographic reports and admission and discharge diagnoses had sensitivity, specificity, positive predictive value, and negative predictive value of 84.7%, 78.2%, 75%, and 87%, respect…
View article: Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment
Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment Open
Cost considerations, not having vaccination recommended to parents and a lack of knowledge among parents of the benefits of PCV to the child may adversely impact PCV uptake in Singapore.